Transforming cryoablation cancer treatment with ProSense™
NEW CLINICAL RESULTS
Published results in Israel treating recurrent kidney tumors after primary nephron-sparing surgery demonstrated a 100% oncologic success in 7 patients. No tumors showed contrast enhancement or growth on follow-up imaging.
IceCure is currently establishing strong clinical foundations in interventional oncology to enable ProSense™ treatment for cancer of the kidney, lung, bone, and prostate.
Clinical trials treating lung and kidney cancer percutaneously under CT with ProSense™ cryoablation are indicating exceptional outcomes in Japan and Israel.
Jason R. Williams, MD
Director of Interventional Oncology,
Williams Cancer Institute,
Atlanta, GA and Mexico City, Mexico
Clinical studies with ProSense™ are currently underway at centers of excellence worldwide.
ProSense™ Treatment of Lung Cancer
Ongoing independent trial, Japan
Dr. Hiroaki Nomori, M.D., Ph.D., Chairman of the Department of General Thoracic Surgery, Kameda Medical Center, Japan
101 patients with T1N0M0 non-small cell lung cancer were treated with ProSense™ Cryoablation System. Investigators found cryoablation using liquid nitrogen to be feasible in the treatment of T1N0M0 NSCLC and to be a promising treatment especially for tumors <1.8cm in size. 
Over 250 patients treated with ProSense™ to date
Three-year follow-up on ~30 T1mi +T1a +T1b cancer patients (<2cm mass) shows overall survival rate of 100% after ProSense™ therapy vs. ~78% after radiation therapy. 
 Hiraki T. Lung Radiofrequency Ablation: Educational Lectures (EL2-1); Cryomedicine 2017: The 44th Annual Meeting of the Japanese Society for Low Temperature Medicine.
 Shprits S. et al., 2019 Cryoablation for recurrent renal tumors after primary nephron-sparing surgery using an innovative liquid nitrogen-based cryogenic device.
Journal of Molecular and Clinical Medicine: 2 (1):11-14.
 Nomori, H. et al, 2020. Cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen. European Journal of Radiology: 133 (2020) 109334
Ongoing trial and collaborative clinical research, Israel
Prof. Ofer Nativ, Head of the Urological Department, Bnai Zion Medical Center, Israel
Dr. Robert Sachner, Head of Interventional Radiology, Bnai Zion Medical Center, Israel
Of 7 patients with tumor recurrence after nephron-sparing surgery, none of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success. Only three adverse events were recorded. Investigators found cryoablation with the ProSense™ system is feasible and effective, with excellent renal function preservation and without major complications. 
Of 74 patients with 78 small kidney masses (≤ 4cm) treated, ProSense™ showed treatment success by lack of enhancement on CT or MRI in 93% (42 of 45) of cases at 1 year follow-up. Investigators found the ProSense™ system to be safe, effective and without serious adverse events.